Bloomberg Opinion, Columnist

Is Johnson & Johnson’s Covid-19 Vaccine a Game Changer?

Having a single-shot solution that’s easy to store would be a great help in the vaccination effort. But there are still some unknowns. 

Johnson & Johnson’s will make a big difference, but it’s not a panacea. 

Photographer: Ben Stansall/AFP via Getty Images

Lock
This article is for subscribers only.

Sam Fazeli, a Bloomberg Opinion contributor who covers the pharmaceutical industry for Bloomberg Intelligence, answered questions about Johnson & Johnson’s one-dose Covid-19 vaccine. The pharmaceutical giant released promising early-stage trial data on its ability to fight the disease, expanding on results the company first published in September. The conversation has been edited and condensed.

Johnson & Johnson’s vaccine will be another weapon in the fight against Covid-19. What do these findings say about how well it works and how it compares with others?